Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations

Condition(s) studied

Investigational drug(s) / intervention(s)

Pancreatic elastase-1 in blood serum: Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.

Study summary

This is a prospective cohort study. The investigators enroll subjects with pancreatic ductal adenocarcinoma (PDAC), individuals at high risk for PDAC, patients with other pancreatic diseases, patients with CA19-9 elevation and controls without pancreatic disease. This study aims to establish a diagnostic prediction model by using elastase 1, common clinical serological examinations, and imaging examinations including endoscopic ultrasonography (EUS), and to explore the diagnostic ability of the model in the high-risk population of PDAC. Besides, the investigators search for new biomarkers by multi-omics studies of serum and pancreatic tissues to further improve the diagnostic performance of this model. In conclusion, this study seeks a robust diagnostic prediction model to diagnose PDAC, especially early resectable PDAC.

Eligibility

Primary outcome measure(s)

• The diagnostic value (sensitivity, specificity, accuracy, and positive and negative predictive values) — 2 years
  The diagnostic value of diagnostic model in diagnosing PDAC, especially early resectable PDAC.

Trial sites (1)

More Qilu Hospital of Shandong University trials in China

Other trials for the same condition